|  |  |
| --- | --- |
| **Country COVID-19 intra-action review (IAR)****Note-taking template: Pillar 10, COVID-19 vaccination****28 April 2021** |  |

**Note-taking template for Country COVID-19 Intra-Action Review (IAR)**

**Pillar 10: COVID-19 Vaccination**

**[COUNTRY]**

**Date(s) of Intra-Action Review: [DD/MM/YYYY**]

|  |
| --- |
| ***Instructions:*** |
|  |
| * *This template will be used by the notetaker during the IAR.*
 |
| * *In the table, the sections on “Best practices” and on “Challenges” should be completed during the session “STEP 1”. The section on “Prioritized actions” should be completed during the session “STEP 2”.*
 |

|  |  |
| --- | --- |
| **PILLAR 10 : COVID-19 Vaccination** | **Document Existing Systems** |
|  |  | **Note if new programme or adaptations to existing systems were required** |
| **1.** | ***Programmes for vaccination of COVID-19 risk groups*** |  |
| **2.** | ***National Immunization Technical Advisory Group (NITAG)*** |  |
| **3.** | ***Adverse events following immunization (AEFI) causality assessment committee*** |  |
|  |  |
| **PILLAR 10 : COVID-19 Vaccination** | **Section A: Regulatory Preparedness** |
| **BEST PRACTICES** | **IMPACT(S)** | **ENABLING FACTORS** |
| 1. | *Best practice 1:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 2. | *Best practice 2:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 3. | *Best practice 3:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| … | … |  |  |
| **CHALLENGES** | **IMPACT(S)** | **LIMITING FACTORS** |
| 1. | *Challenge 1:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 2. | *Challenge 2:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 3. | *Challenge 3:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| … | … |  |  |

|  |  |
| --- | --- |
| **PILLAR 10 : COVID-19 Vaccination** | **Section B: Planning, Coordination, & Service Delivery** |
| **BEST PRACTICES** | **IMPACT(S)** | **ENABLING FACTORS** |
| 1. | *Best practice 1:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 2. | *Best practice 2:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 3. | *Best practice 3:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| … | … |  |  |
| **CHALLENGES** | **IMPACT(S)** | **LIMITING FACTORS** |
| 1. | *Challenge 1:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 2. | *Challenge 2:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 3. | *Challenge 3:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| … | … |  |  |

|  |  |
| --- | --- |
| **PILLAR 10 : COVID-19 Vaccination** | **Section C: Funding** |
| **BEST PRACTICES** | **IMPACT(S)** | **ENABLING FACTORS** |
| 1. | *Best practice 1:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 2. | *Best practice 2:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 3. | *Best practice 3:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| … | … |  |  |
| **CHALLENGES** | **IMPACT(S)** | **LIMITING FACTORS** |
| 1. | *Challenge 1:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 2. | *Challenge 2:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 3. | *Challenge 3:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| … | … |  |  |

|  |  |
| --- | --- |
| **PILLAR 10 : COVID-19 Vaccination** | **Section D: Supply Chain & Waste Management**  |
| **BEST PRACTICES** | **IMPACT(S)** | **ENABLING FACTORS** |
| 1. | *Best practice 1:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 2. | *Best practice 2:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 3. | *Best practice 3:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| … | … |  |  |
| **CHALLENGES** | **IMPACT(S)** | **LIMITING FACTORS** |
| 1. | *Challenge 1:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 2. | *Challenge 2:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 3. | *Challenge 3:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| … | … |  |  |

|  |  |
| --- | --- |
| **PILLAR 10 : COVID-19 Vaccination** | **Section E: Human Resource Management & Training** |
| **BEST PRACTICES** | **IMPACT(S)** | **ENABLING FACTORS** |
| 1. | *Best practice 1:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 2. | *Best practice 2:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 3. | *Best practice 3:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| … | … |  |  |
| **CHALLENGES** | **IMPACT(S)** | **LIMITING FACTORS** |
| 1. | *Challenge 1:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 2. | *Challenge 2:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 3. | *Challenge 3:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| … | … |  |  |

|  |  |
| --- | --- |
| **PILLAR 10 : COVID-19 Vaccination** | **Section F: Vaccine Acceptance & Demand** |
| **BEST PRACTICES** | **IMPACT(S)** | **ENABLING FACTORS** |
| 1. | *Best practice 1:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 2. | *Best practice 2:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 3. | *Best practice 3:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| … | … |  |  |
| **CHALLENGES** | **IMPACT(S)** | **LIMITING FACTORS** |
| 1. | *Challenge 1:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 2. | *Challenge 2:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 3. | *Challenge 3:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| … | … |  |  |

|  |  |
| --- | --- |
| **PILLAR 10 : COVID-19 Vaccination** | **Section G: Vaccine Safety**  |
| **BEST PRACTICES** | **IMPACT(S)** | **ENABLING FACTORS** |
| 1. | *Best practice 1:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 2. | *Best practice 2:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 3. | *Best practice 3:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| … | … |  |  |
| **CHALLENGES** | **IMPACT(S)** | **LIMITING FACTORS** |
| 1. | *Challenge 1:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 2. | *Challenge 2:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 3. | *Challenge 3:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| … | … |  |  |

|  |  |
| --- | --- |
| **PILLAR 10 : COVID-19 Vaccination** | **Section H: Monitoring & Evaluation** |
| **BEST PRACTICES** | **IMPACT(S)** | **ENABLING FACTORS** |
| 1. | *Best practice 1:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 2. | *Best practice 2:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| 3. | *Best practice 3:* | *Impact 1:**Impact 2:* | *Enabling factor 1:**Enabling factor 2:**Enabling factor 3:* |
| … | … |  |  |
| **CHALLENGES** | **IMPACT(S)** | **LIMITING FACTORS** |
| 1. | *Challenge 1:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 2. | *Challenge 2:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| 3. | *Challenge 3:* | *Impact 1:**Impact 2:* | *Limiting factor 1:**Limiting factor 2:**Limiting factor 3:* |
| … | … |  |  |

|  |  |
| --- | --- |
| **PILLAR 10 : COVID-19 Vaccination** | **Improve the ongoing COVID-19 vaccine roll-out**  |
| 1. | *What is the number one thing you would do differently or change about the COVID-19 vaccination programme going forward?* |  |
| 2. | *What best practices can be identified from the country’s implementation of COVID-19 immunization, and how can these be further strengthened and instituted?* |  |
| 3. | *What is the most important piece of advice you would give another country just starting their program?* |  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **PRIORITIZED ACTIONS** | **TIMELINE & DESIRED DATE FOR COMPLETION** | **RESPONSIBLE FOCAL POINT** | **ESTIMATED BUDGET AND FINANCIAL SOURCE** | **REQUIRED SUPPORT** | **INDICATORS** |
| 1. For immediate implementation:
 |
| 1. |  |  |  |  |  |  |
|  |  |
|  |  |
| 2. |  |  |  |  |  |  |
|  |  |
|  |  |
| 3. |  |  |  |  |  |  |
|  |  |
|  |  |
| … | … |  |  |  |  |  |
|  |  |
|  |  |
| 1. For mid to long-term implementation to improve the ongoing response to COVID-19 outbreak (including for next waves):
 |
| 1. |  |  |  |  |  |  |
|  |  |
|  |  |
| 2. |  |  |  |  |  |  |
|  |  |
|  |  |
| 3. |  |  |  |  |  |  |
|  |  |
|  |  |
| … |  |  |  |  |  |  |
|  |  |
|  |  |

**©** World Health Organization 2021. Some rights reserved. This work is available under the [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo) licence.

WHO reference number : WHO/2019-nCoV/Country\_IAR/templates/note\_taking/vaccination/2021.1